Study on mechanism of Salvia miltiorrhiza treating cardiovascular disease through auxiliary mechanism elucidation system for Chinese medicine.
- Author:
Shuai-bing HE
;
Bai-xia ZHANG
;
Hui-hui WANG
;
Yun WANG
;
Yan-jiang QIAO
- Publication Type:Journal Article
- MeSH:
Animals;
Cardiovascular Diseases;
drug therapy;
genetics;
metabolism;
Databases, Factual;
Drugs, Chinese Herbal;
administration & dosage;
chemistry;
Gene Regulatory Networks;
drug effects;
Humans;
Salvia miltiorrhiza;
chemistry;
Signal Transduction
- From:
China Journal of Chinese Materia Medica
2015;40(19):3713-3717
- CountryChina
- Language:Chinese
-
Abstract:
Salvia miltiorrhiza is a traditional Chinese medicine (TCM) and is widely used as a clinically medication for its efficiency in treating cardiovascular disease. Due to TCM is a comprehensive system, the mechanism of S. miltiorrhiza treating cardiovascular disease through integrated multiple pathways are still unclear in some aspects. With the rapid progress of bioinformatics and systems biology, network pharmacology is considered as a promising approach toward reveal the underlying complex relationship between an herb and the disease. In order to discover the mechanism of S. miltiorrhiza treating cardiovascular disease systematically, we use the auxiliary mechanism elucidation system for Chinese medicine, built up a molecule interaction network on the active component targets of S. miltiorrhiza and the therapeutic targets of cardiovascular disease to offer an opportunity for deep understanding the mechanism of S. miltiorrhiza treating cardiovascular disease from the perspective of network pharmacology. The results showed that S. miltiorrhiza treating cardiovascular disease through ten pathways as follows: improve lipid metabolism, anti-inflammation, regulate blood pressure, negatively regulates blood coagulation factor and antithrombotic, regulate cell proliferation, anti-stress injury, promoting angiogenesis, inhibited apoptosis, adjust vascular systolic and diastolic, promoting wound repair. The results of this paper provide theoretical guidance for the development of new drugs to treat cardiovascular disease and the discovery of new drugs through component compatibility.
